{"name":"Wan-Guang Zhang","slug":"wan-guang-zhang","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Camrelizumab plus Apatinib","genericName":"Camrelizumab plus Apatinib","slug":"camrelizumab-plus-apatinib","indication":"Advanced gastric cancer","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Nocardia rubra cell wall skeleton","genericName":"Nocardia rubra cell wall skeleton","slug":"nocardia-rubra-cell-wall-skeleton","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Camrelizumab plus Apatinib","genericName":"Camrelizumab plus Apatinib","slug":"camrelizumab-plus-apatinib","phase":"phase_2","mechanism":"Camrelizumab is a PD-1 inhibitor, and Apatinib is a VEGFR-2 tyrosine kinase inhibitor.","indications":["Advanced gastric cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"Nocardia rubra cell wall skeleton","genericName":"Nocardia rubra cell wall skeleton","slug":"nocardia-rubra-cell-wall-skeleton","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}